A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients with Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
Price : $35 *
At a glance
- Drugs ZSTK 474 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Zenyaku Kogyo
- 31 Mar 2016 Status changed from recruiting to completed.
- 15 Jan 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 15 Jan 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.